AKBA

AKBA

USD

Akebia Therapeutics Inc. Common Stock

$2.125+0.025 (1.190%)

即時價格

Healthcare
Drug Manufacturers - Specialty & Generic
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$2.100

最高

$2.145

最低

$2.070

交易量

4.47M

公司基本面

市值

563.4M

行業

Drug Manufacturers - Specialty & Generic

國家

United States

交易統計

平均交易量

4.04M

交易所

NCM

貨幣

USD

52週範圍

最低 $1.52當前 $2.125最高 $4.079

相關新聞

GlobeNewswire

Akebia Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced

查看更多
Akebia Therapeutics to Present at Upcoming Investor Conferences
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $6

HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics with a Buy and lowers the price target from $8 to $6.

查看更多
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $6
Analyst Upgrades

BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $5

BTIG analyst Julian Harrison maintains Akebia Therapeutics with a Buy and lowers the price target from $10 to $5.

查看更多
BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $5
GlobeNewswire

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced

查看更多
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients